Recent Finacing
Recent Raise
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing orally bioavailable small-molecule therapies using a muscle-physiology platform; its lead candidate EDG-5506 targets injurious hypercontraction in Duchenne and Becker muscular dystrophies.
